Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNSF.L Regulatory News (NSF)

  • There is currently no data for NSF

Director/PDMR Shareholding

3 Aug 2018 09:56

RNS Number : 7718W
Non-Standard Finance PLC
03 August 2018
ย 

Non-Standard Finance plc

('NSF', the 'Company' or the 'Group')

Director/PDMR Shareholding

3 August 2018

ย 

NSF was informed on 2 August 2018 that Miles Cresswell-Turner, his wife (Fusca Millo) and his daughters (Flavia Cresswell-Turner & Allegra Cresswell-Turner) had all purchased shares in the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

ย 

1

ย 

Details of the person discharging managerial responsibilities / person closely associated

ย 

a)

ย 

Name

ย 

ย 

1. Miles Cresswell-Turner

2. Fusca Millo

3. Flavia Cresswell-Turner

4.ย Allegra Cresswell-Turner

2

ย 

Reason for the notification

ย 

a)

ย 

Position/status

ย 

ย 

1. Executive Director of the Company and Chief Executive

Officer of Everyday Loans

2. Wife of Miles Creswell-Turner

3. Daughter of Miles Cresswell-Turner

4. Daughter of Miles Cresswell-Turnerย 

b)

ย 

Initial notification /Amendment

ย 

ย 

Initial notification

3

ย 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

ย 

a)

ย 

Name

ย 

ย 

Non-Standard Finance plc

b)

ย 

LEI

ย 

ย 

213800DVBNIJ1J2OF119

4

ย 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

ย 

ย 

a)

ย 

Description of the financial instrument, type of instrument

ย 

Identification code

ย 

ย 

Ordinary shares of 5p each in the capital of Non-Standard Finance plc

ย 

GB00BRJ6JV17

b)

ย 

Nature of the transaction

ย 

ย 

Purchase of Ordinary Shares

c)

ย 

Price(s) and volume(s)

ย 

ย 

ย 

Price(s)

ย 

Volume(s)

1.

59.188 pence

59.8 pence

61.39 pence

61.5 pence

61.712 pence

ย 

25,342 shares

25,083 shares

24,433 shares

24,390 shares

16,204 shares

2.

58.18 pence

60.4 pence

17,000 shares

16,554 shares

2.

58.07 pence

8,450 shares

2.

59.38 pence

8,420 shares

d)

ย 

Aggregated information

ย 

ย 

- Aggregated volume

- Price

ย 

ย 

1. 115,452 shares at a total cost of ยฃ69,998.14

2. 33,554 shares at a total cost of ยฃ 19,889.22

3. 8,450 shares at a total cost of ยฃ4,906.92

4. 8,420 shares at a total cost of ยฃ4,999.80

e)

ย 

Date of the transaction

ย 

ย 

02 August 2018

f)

ย 

Place of the transaction

ย 

ย 

London Stock Exchange (XLON)

As a result of today's purchase Miles Cresswell-Turner and his immediate family hold in aggregate 672,059 shares in the Company.

ย 

Enquiries:

ย 

Non-Standard Finance plc

Peter Reynolds, Director, IR and Communications

+44 (0) 20 3869 9026

ย 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
ย 
END
ย 
ย 
DSHFKNDPFBKKPFK
Date   Source Headline
10th Jul 20237:00 amRNSNotice of Delisting
7th Jul 20238:06 amRNSSuspension of Trading in Ordinary Shares
5th Jul 20233:18 pmRNSUpdate on Delisting and Suspension of Shares
23rd Jun 20232:51 pmRNSFiling of Annual General Meeting Resolutions
23rd Jun 20232:49 pmRNSResult of AGM
23rd Jun 20237:00 amRNSUpdate on Scheme, Delisting & Directorate Change
23rd May 20237:00 amRNSStandard form for notification of major holdings
18th May 20237:00 amRNSProposed Recapitalisation & Directorate Change 
28th Apr 20235:51 pmRNSReplacement: Update on scheme of arrangement
28th Apr 20233:33 pmRNSUpdate on scheme of arrangement
28th Apr 20238:21 amRNSAudited full year results to 31 December 2022
14th Apr 20237:00 amRNSProposed Release of Debt and Directorate Change
4th Apr 20234:14 pmRNSDirector/PDMR Shareholding
29th Mar 20234:35 pmRNSPrice Monitoring Extension
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:39 amRNSLaunch of Scheme & Proposed Recapitalisation
17th Mar 20237:00 amRNSScheme of Launch & Proposed Recapitalisation
13th Feb 20237:00 amRNS2022 Trading Statement
4th Jan 202310:15 amRNSDirector/PDMR Shareholding
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
4th Oct 20224:40 pmRNSSecond Price Monitoring Extn
4th Oct 20224:35 pmRNSPrice Monitoring Extension
29th Sep 20225:50 pmRNSDirector/PDMR Shareholding
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension
28th Sep 20227:05 amRNSUpdate on Current Status and Regulatory matters
28th Sep 20227:05 amRNSUnaudited Half Year Results to 30 June 2022
27th Jul 20224:41 pmRNSSecond Price Monitoring Extn
27th Jul 20224:36 pmRNSPrice Monitoring Extension
22nd Jul 20224:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20224:41 pmRNSSecond Price Monitoring Extn
19th Jul 20224:35 pmRNSPrice Monitoring Extension
6th Jul 20224:40 pmRNSSecond Price Monitoring Extn
6th Jul 20224:36 pmRNSPrice Monitoring Extension
4th Jul 20224:16 pmRNSDirector/PDMR Shareholding
15th Jun 20223:25 pmRNSFunding facilities update
26th May 20224:42 pmRNSFilings of AGM Resolutions
26th May 20222:49 pmRNSResults of Annual General Meeting
29th Apr 202212:00 pmRNSDirectorate Change
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
1st Apr 20224:40 pmRNSSecond Price Monitoring Extn
1st Apr 20224:35 pmRNSPrice Monitoring Extension
29th Mar 20229:26 amRNSDirector/PDMR Shareholding
17th Mar 20224:41 pmRNSSecond Price Monitoring Extn
17th Mar 20224:36 pmRNSPrice Monitoring Extension
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.